Caribou Biosciences, Inc. (CRBU)

Caribou Biosciences' stock has experienced volatility in the past six months. The stock rose approximately 12% over the past quarter due to positive earnings and pipeline progress, but declined by about 10% in the last 30 days due to clinical updates and financing concerns. Positive clinical data from vispa-cel and CB-011 boosted confidence in November 2025. Caribou Biosciences reported its Fourth Quarter and Full Year 2025 financial results on March 5, 2026, which included a significant year-over-year revenue increase in Q4 2025 and an earnings beat, and the FDA granted RMAT Designation to CB-011. Concerns were raised about drug pricing reforms on March 7, 2026. Leerink Partners and Clear Street reiterated their "Buy" ratings for CRBU on March 11, 2026, and Truist Financial upgraded Caribou Biosciences on March 28, 2026. The company has faced challenges related to cash burn and insider selling transactions.

Caribou Biosciences, Inc. does not exhibit traditional demand seasonality. The demand for its product candidates is driven by clinical trial progression, regulatory approvals, and the medical need for treatments for specific cancers.

Caribou Biosciences, Inc. (CRBU) is a clinical-stage biopharmaceutical company utilizing its CRISPR-Cas gene-editing platform to develop cell therapies for diseases like hematologic malignancies. Their technology enables precise modification of cellular genomes to create allogeneic CAR-T cell therapies. The company's major product candidates include vispa-cel for B cell non-Hodgkin lymphoma, CB-011 for multiple myeloma, and CB-012 for hematologic cancers, all in Phase 1 clinical trials.

Caribou Biosciences, Inc. is headquartered in Berkeley, California, and operates geographically in the United States and the rest of the world, with the United States generating the most revenue.

Caribou Biosciences' brand reputation has been influenced by clinical trial progress, analyst sentiment, and legal challenges. The company has received a consensus rating of "Moderate Buy" to "Strong Buy" from analysts. Positive clinical data from the vispa-cel ANTLER Phase 1 trial and CB-011, along with the FDA RMAT Designation for CB-011, have contributed positively. However, a class action lawsuit alleging overstated safety, efficacy, and durability of CB-010, as well as concerns about cash sufficiency and a workforce reduction, have negatively impacted its reputation.

Caribou Biosciences, Inc. has a mixed ownership structure. Institutional investors hold a significant portion of the company’s stock, with major shareholders including Pfizer Inc., Vanguard Group Inc., BlackRock, Inc., Kynam Capital Management, LP, and Renaissance Technologies Llc. Insiders own approximately 8.91% to 9.50% of the stock, with CEO Rachel E. Haurwitz being the largest individual shareholder. Retail investors hold a substantial portion, estimated at 52.67% to 68.83%.